Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuko Matsushima

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Clinical Pharmacology in Drug Development|September 23, 2016
Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese SubjectsKazuo Umemura, Yasuhiko Ikeda, Nobuko Matsushima, et al.
Journal of Personalized Medicine|March 25, 2022
Current Status, Issues and Future Prospects of Personalized Medicine for Each DiseaseYuichi Yamamoto, Norihiro Kanayama, Yusuke Nakayama, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 31, 2006
Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response modelsWojciech Krzyzanski, Jacek Dmochowski, Nobuko Matsushima, et al.
Journal of Clinical Pharmacology|August 5, 2015
A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc intervalJeanne Mendell, Nobuko Matsushima, Terry E O'Reilly, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsNobuko Matsushima, Frank Lee, Toshiyuki Sato, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2016
Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumorsSatoshi Yoshiba, Mendel Jansen, Nobuko Matsushima, et al.
Intestinal Research|November 17, 2017
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studiesToshifumi Hibi, Yuya Imai, Yoko Murata, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 3, 2007
Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometryDongyang Liu, Pei Hu, Nobuko Matsushima, et al.
Drug Metabolism and Pharmacokinetics|October 30, 2021
Pharmacokinetics and safety of rilpivirine in healthy Japanese subjects and exploration of ethnic sensitivity of rilpivirine pharmacokinetics with physiologically based pharmacokinetic model approachKentaro Ohta, Nobuko Matsushima, Hiromi Tanii, et al.
British Journal of Clinical Pharmacology|August 18, 2016
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporineDolly A Parasrampuria, Jeanne Mendell, Minggao Shi, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology in Drug Development|September 23, 2016
Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese SubjectsKazuo Umemura, Yasuhiko Ikeda, Nobuko Matsushima, et al.
Journal of Personalized Medicine|March 25, 2022
Current Status, Issues and Future Prospects of Personalized Medicine for Each DiseaseYuichi Yamamoto, Norihiro Kanayama, Yusuke Nakayama, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 31, 2006
Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response modelsWojciech Krzyzanski, Jacek Dmochowski, Nobuko Matsushima, et al.
Journal of Clinical Pharmacology|August 5, 2015
A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc intervalJeanne Mendell, Nobuko Matsushima, Terry E O'Reilly, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsNobuko Matsushima, Frank Lee, Toshiyuki Sato, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2016
Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumorsSatoshi Yoshiba, Mendel Jansen, Nobuko Matsushima, et al.
Intestinal Research|November 17, 2017
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studiesToshifumi Hibi, Yuya Imai, Yoko Murata, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 3, 2007
Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometryDongyang Liu, Pei Hu, Nobuko Matsushima, et al.
Drug Metabolism and Pharmacokinetics|October 30, 2021
Pharmacokinetics and safety of rilpivirine in healthy Japanese subjects and exploration of ethnic sensitivity of rilpivirine pharmacokinetics with physiologically based pharmacokinetic model approachKentaro Ohta, Nobuko Matsushima, Hiromi Tanii, et al.
British Journal of Clinical Pharmacology|August 18, 2016
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporineDolly A Parasrampuria, Jeanne Mendell, Minggao Shi, et al.
Pageof 3